March 10, 2026
Aurobindo Receives FDA Approval for Siponimod Tablets, 0.25mg, 1mg, and 2mg
East Windsor, N.J. – Aurobindo Pharma Limited has received final approval from U.S. Food and Drug Administration for its Abbreviated New Drug Application Siponimod Tablets, 0.25mg, 1mg, and2 mg . Aurobindo Pharma’s Siponimod Tablets are an AB-rated generic equivalent to the reference listed drug (RLD), Mayzent® Tablets manufactured by Novartis Pharmaceuticals Corporation. Siponimod Tablets are […]
